Cargando…

Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds

BACKGROUND: The purpose of the current study was to determine the final content validation, psychometric characteristics, clinically meaningful improvement, and responder thresholds of the Clostridium difficile infection (CDI)–Daily Symptoms (CDI-DaySyms™) patient-reported outcome (PRO) questionnair...

Descripción completa

Detalles Bibliográficos
Autores principales: Talbot, George H., Kleinman, Leah, Davies, Evan, Hunsche, Elke, Revicki, Dennis, Roberts, Laurie, Rosenberg, Daniel, Nord, Carl Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499966/
https://www.ncbi.nlm.nih.gov/pubmed/31053093
http://dx.doi.org/10.1186/s12955-019-1142-9
_version_ 1783415860514258944
author Talbot, George H.
Kleinman, Leah
Davies, Evan
Hunsche, Elke
Revicki, Dennis
Roberts, Laurie
Rosenberg, Daniel
Nord, Carl Erik
author_facet Talbot, George H.
Kleinman, Leah
Davies, Evan
Hunsche, Elke
Revicki, Dennis
Roberts, Laurie
Rosenberg, Daniel
Nord, Carl Erik
author_sort Talbot, George H.
collection PubMed
description BACKGROUND: The purpose of the current study was to determine the final content validation, psychometric characteristics, clinically meaningful improvement, and responder thresholds of the Clostridium difficile infection (CDI)–Daily Symptoms (CDI-DaySyms™) patient-reported outcome (PRO) questionnaire. METHODS: This validation study was part of two phase III studies (NCT01987895 and NCT01983683) conducted in patients with mild-to-moderate or severe CDI who completed the CDI-DaySyms™ daily throughout the treatment period. The questionnaire was evaluated in three stages: final PRO item content validation (Stage I); psychometric evaluation of reliability and construct validity (Stage II); and determination of clinically meaningful improvement and responder thresholds using distribution-based methods (Stage III). RESULTS: The analysis included 168 patients. Most patients were female and Caucasian with mild-to-moderate CDI. The mean age was 57.1 years. Initial item analysis supported by confirmatory factor analysis demonstrated the relevance of 10 items grouped into three distinct domains (Diarrhea Symptoms, Abdominal Symptoms, and Systemic/Other Symptoms). Domain scores demonstrated acceptable internal consistency and test-retest reliability, were sensitive to change, and correlated in expected directions with other relevant symptom and disease-severity measures. Responder thresholds were defined as score changes of − 1.00, − 0.80, and − 0.70 in the Diarrhea Symptoms, Abdominal Symptoms, and Systemic/Other Symptoms domains, respectively. CONCLUSIONS: The CDI-DaySyms™ is a valid measure of patient-reported CDI symptoms, with good measurement properties, which supports its utility as an endpoint in clinical studies. Further studies confirming responder thresholds based on anchor-based methods are required. TRIAL REGISTRATION: NCT01987895, registered November 20, 2013; NCT01983683, registered November 14, 2013. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-019-1142-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6499966
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64999662019-05-09 Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds Talbot, George H. Kleinman, Leah Davies, Evan Hunsche, Elke Revicki, Dennis Roberts, Laurie Rosenberg, Daniel Nord, Carl Erik Health Qual Life Outcomes Research BACKGROUND: The purpose of the current study was to determine the final content validation, psychometric characteristics, clinically meaningful improvement, and responder thresholds of the Clostridium difficile infection (CDI)–Daily Symptoms (CDI-DaySyms™) patient-reported outcome (PRO) questionnaire. METHODS: This validation study was part of two phase III studies (NCT01987895 and NCT01983683) conducted in patients with mild-to-moderate or severe CDI who completed the CDI-DaySyms™ daily throughout the treatment period. The questionnaire was evaluated in three stages: final PRO item content validation (Stage I); psychometric evaluation of reliability and construct validity (Stage II); and determination of clinically meaningful improvement and responder thresholds using distribution-based methods (Stage III). RESULTS: The analysis included 168 patients. Most patients were female and Caucasian with mild-to-moderate CDI. The mean age was 57.1 years. Initial item analysis supported by confirmatory factor analysis demonstrated the relevance of 10 items grouped into three distinct domains (Diarrhea Symptoms, Abdominal Symptoms, and Systemic/Other Symptoms). Domain scores demonstrated acceptable internal consistency and test-retest reliability, were sensitive to change, and correlated in expected directions with other relevant symptom and disease-severity measures. Responder thresholds were defined as score changes of − 1.00, − 0.80, and − 0.70 in the Diarrhea Symptoms, Abdominal Symptoms, and Systemic/Other Symptoms domains, respectively. CONCLUSIONS: The CDI-DaySyms™ is a valid measure of patient-reported CDI symptoms, with good measurement properties, which supports its utility as an endpoint in clinical studies. Further studies confirming responder thresholds based on anchor-based methods are required. TRIAL REGISTRATION: NCT01987895, registered November 20, 2013; NCT01983683, registered November 14, 2013. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12955-019-1142-9) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-03 /pmc/articles/PMC6499966/ /pubmed/31053093 http://dx.doi.org/10.1186/s12955-019-1142-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Talbot, George H.
Kleinman, Leah
Davies, Evan
Hunsche, Elke
Revicki, Dennis
Roberts, Laurie
Rosenberg, Daniel
Nord, Carl Erik
Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
title Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
title_full Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
title_fullStr Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
title_full_unstemmed Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
title_short Clostridium difficile Infection–Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds
title_sort clostridium difficile infection–daily symptoms (cdi-daysyms™) questionnaire: psychometric characteristics and responder thresholds
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499966/
https://www.ncbi.nlm.nih.gov/pubmed/31053093
http://dx.doi.org/10.1186/s12955-019-1142-9
work_keys_str_mv AT talbotgeorgeh clostridiumdifficileinfectiondailysymptomscdidaysymsquestionnairepsychometriccharacteristicsandresponderthresholds
AT kleinmanleah clostridiumdifficileinfectiondailysymptomscdidaysymsquestionnairepsychometriccharacteristicsandresponderthresholds
AT daviesevan clostridiumdifficileinfectiondailysymptomscdidaysymsquestionnairepsychometriccharacteristicsandresponderthresholds
AT hunscheelke clostridiumdifficileinfectiondailysymptomscdidaysymsquestionnairepsychometriccharacteristicsandresponderthresholds
AT revickidennis clostridiumdifficileinfectiondailysymptomscdidaysymsquestionnairepsychometriccharacteristicsandresponderthresholds
AT robertslaurie clostridiumdifficileinfectiondailysymptomscdidaysymsquestionnairepsychometriccharacteristicsandresponderthresholds
AT rosenbergdaniel clostridiumdifficileinfectiondailysymptomscdidaysymsquestionnairepsychometriccharacteristicsandresponderthresholds
AT nordcarlerik clostridiumdifficileinfectiondailysymptomscdidaysymsquestionnairepsychometriccharacteristicsandresponderthresholds